$Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease$

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease

A study in patients with chronic GVHD evaluated three doses of axatilimab, a colony-stimulating factor 1 receptor antibody. The lowest dose appeared to maximize response with the fewest adverse effects.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-09, Vol.391 (11), p.1002-1014
Hauptverfasser:	Wolff, Daniel, Cutler, Corey, Lee, Stephanie J., Pusic, Iskra, Bittencourt, Henrique, White, Jennifer, Hamadani, Mehdi, Arai, Sally, Salhotra, Amandeep, Perez-Simon, Jose A., Alousi, Amin, Choe, Hannah, Kwon, Mi, Bermúdez, Arancha, Kim, Inho, Socié, Gerard, Chhabra, Saurabh, Radojcic, Vedran, O’Toole, Timothy, Tian, Chuan, Ordentlich, Peter, DeFilipp, Zachariah, Kitko, Carrie L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Adverse events Aged Aged, 80 and over Allergy Allografts Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Blocking antibodies Body weight Bone Marrow Transplantation Cancer Child Chronic Disease - drug therapy Colony-stimulating factor Confidence intervals Dose-Response Relationship, Drug Enrollments FDA approval Female Genetics Genetics General Graft versus host disease Graft vs Host Disease - diagnosis Graft vs Host Disease - drug therapy Graft vs Host Disease - immunology Graft vs Host Disease - metabolism Graft-versus-host reaction Hematology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic stem cells Humans Immunity Immunology Immunology General Inflammatory Disease Infusions, Intravenous Leukemia Lymphoma Macrophage colony-stimulating factor Macrophages Male Middle Aged Monocytes Oncology Patients Pharmaceuticals Pharmacodynamics Pharmacokinetics Receptor, Macrophage Colony-Stimulating Factor - antagonists & inhibitors Receptor, Macrophage Colony-Stimulating Factor - metabolism Recurrence Severity of Illness Index Stem cell transplantation T-Cells Transplants & implants Treatment Outcome Treatments in Oncology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A study in patients with chronic GVHD evaluated three doses of axatilimab, a colony-stimulating factor 1 receptor antibody. The lowest dose appeared to maximize response with the fewest adverse effects.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2401537